Brittany Meiling – Page 3 – Endpoints News

about the author

Brittany Meiling

editors@endpointsnews.com

Brittany Meiling on LinkedIn

author articles

Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

7 years ago

Ipsen adds coworking to new Boston HQ with BioLabs partnership; NYC gets biotech startup accelerator, funded with ...

7 years ago

In two PhIII wins for Allergan/Molecular Partners, wet AMD drug shows non-inferiority to Lucentis

7 years ago

After billion-dollar drug deal, patient death and trial hold cripple Mersana's shares

7 years ago

Armed with $36M A round, Johns Hopkins spinout Neuraly heads to PhI Parkinson's trial

7 years ago

Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program

7 years ago

The next Nimbus? Head of billion-dollar drug program launches HotSpot with $45M A round

7 years ago

Taking on biodefense threats, antibiotics maker Spero inks $54M in government deals

7 years ago

Backers of Tesla and SpaceX fund 29-year-old Alice Zhang's AI-powered neuroscience startup

7 years ago

Taiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China

7 years ago

After long delay following patient death, FDA lifts trial hold on Advaxis/AstraZeneca combo

7 years ago

On the heels of GW's epilepsy win, Wall Street darling Zogenix shares positive PhIII data on rival drug

7 years ago

Hoping to shake Allergan/Shire's dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

7 years ago

VC money booms in Q2, with mega-deals hitting record levels

7 years ago

Thiel-backed Compass adds $49M to A round, bringing total to $132M

7 years ago

Pfizer reshuffles, splitting into three business units

7 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

7 years ago

Under pressure from shareholders, BioCryst drops plan to merge with Idera

7 years ago

7 things you need to know now about raising biotech cash in China (Part 1)

7 years ago

A roaring Rubius sets out to snag $1.8B market cap in $200M IPO

7 years ago

China to cut cancer drug prices; Nimbus nabs Gilead's Adrian Ray to serve as SVP of discovery biology

7 years ago

Cash-rich Cambridge startup Rubius to build $155M cell therapy manufacturing site in Rhode Island

7 years ago

Appeasing activist investors, Ironwood cuts 40 staffers at the start of company split

7 years ago

With tech from Spinraza's maker, French startup Dynacure gets $55M to tackle neuromuscular disease

7 years ago

First page Previous page 1 234 5 6 Next page Last page